The FDA on Friday revoked its authorization for Eli Lilly’s Covid-19 antibody product bamlanivimab to be used on its own.
Variants of the SARS-CoV-2 virus that causes Covid-19 are on the rise, and those strains are resistant to bamlanivimab alone. Using the Eli Lilly antibody product on its own leads to an “increased risk of treatment failure,” the agency said in a statement Friday.
Consequently, the benefits of the product as a solo treatment for Covid-19 don’t outweigh its risks, and an emergency authorization is unnecessary, according to the Food and Drug Administration.
The move comes as cases and hospitalizations...